ERBB2 and non-small cell lung carcinoma: The percentage of HER2 IHC 3+ or 2+/CNV positive was 18.5%, 8.1%, 6.7%, 10%, 16%, 28.6%, 5.1%, and 3.1% in breast cancer, NSCLC, colorectal, esophago-gastric, urothelial/bladder, biliary, ovarian cancer and pancreas [29].